Amendment to Schedule 13D for Trinity Biotech plc

Perceptive Advisors LLC and its affiliates (collectively, "Perceptive") have filed an amendment to Schedule 13D regarding their holdings in Trinity Biotech plc. The amendment details transactions including a Second Amendment to the Credit Agreement, which involves the issuance of a convertible promissory note to Credit Fund III, convertible into ADSs. Additionally, a Conversion Rights Agreement allows Credit Fund II to satisfy obligations by converting them into ADSs. These conversions are subject to a Beneficial Ownership Cap of 9.9% of outstanding shares. Perceptive has also entered into a Deed Poll to waive voting rights on excess shares. The company is obligated to file a resale registration statement for these securities by January 14, 2025.